Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
Xconomy
JUNE 1, 2018
Among other news, expect a post-mortem analysis of a once-promising immunotherapy combination that included so-called IDO inhibitors, which were at the top of the cancer combo hopefuls list just a short time ago. Many ASCO attendees will zero in on potential cancer drug combinations.
Let's personalize your content